Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
Clinical Cancer Research2011Vol. 17(18), pp. 6021–6028
Citations Over TimeTop 1% of 2011 papers
Irfan Kayani, Norbert Avril, Jamshed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter J. Ell, Andrew R. Reynolds, Thomas Powles
Abstract
Baseline FDG-PET/CT yields prognostic significant data. FDG-PET/CT responses occur in the majority of patients after 4 weeks of therapy; however, it is not until 16 weeks when the results become prognostically significant.
Related Papers
- → Sunitinib resistance in renal cell carcinoma(2014)70 cited
- → Pharmacokinetic–Pharmacodynamic Analysis of Sunitinib-Induced Thrombocytopenia in Japanese Patients with Renal Cell Carcinoma(2015)16 cited
- Molecular mechanisms of sunitinib resistance in renal cell carcinoma(2014)
- The clinical characteristics of hypothyroidism after sunitinib treatment in a Korean population(2009)
- → Abstract 1377: Characterisation of mechanisms of resistance to sunitinib in a unique pre-clinical RCC model(2012)